Log in

Relevant bibliographies by topics / 11C-Deuterium-L-deprenyl / Journal articles

To see the other types of publications on this topic, follow the link: 11C-Deuterium-L-deprenyl.

Journal articles on the topic '11C-Deuterium-L-deprenyl'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 18 journal articles for your research on the topic '11C-Deuterium-L-deprenyl.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Logan, Jean, Joanna S. Fowler, Nora D. Volkow, Gene-Jack Wang, Robert R. MacGregor, and Colleen Shea. "Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain." Nuclear Medicine and Biology 27, no. 1 (2000): 43–49. http://dx.doi.org/10.1016/s0969-8051(99)00088-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rodriguez-Vieitez, Elena, Stephen F. Carter, Konstantinos Chiotis, et al. "Comparison of Early-Phase 11C-Deuterium-L-Deprenyl and 11C-PiB PET for Assessing Brain Perfusion in Alzheimer's Disease." Journal of Nuclear Medecine 57, no. 7 (2016): 1071–7. https://doi.org/10.2967/jnumed.115.168732.

Full text

Abstract:

The PET tracer <sup>11</sup>C-deuterium-L-deprenyl (<sup>11</sup>C-DED) has been used to visualize activated astrocytes in vivo in patients with Alzheimer's disease (AD). In this multitracer PET study, early-phase <sup>11</sup>C-DED and <sup>11</sup>C-Pittsburgh compound-B (<sup>11</sup>C-PiB) (eDED and ePiB, respectively) were compared as surrogate markers of brain perfusion, and the extent to which <sup>11</sup>C-DED binding is influenced by brain perfusion was investigated. METHODS:<sup> 11</sup>C-DED, <sup>11</sup>C-PiB and <sup>18</sup>F-fluorodeoxyglucose (FDG) dynamic PET scans were

APA, Harvard, Vancouver, ISO, and other styles

3

Vilaplana, Eduard, Elena Rodriguez-Vieitez, Daniel Ferreira, et al. "Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease." Neurology 94, no. 19 (2020): e2026-e2036. http://dx.doi.org/10.1212/wnl.0000000000009405.

Full text

Abstract:

ObjectiveTo study the macrostructural and microstructural MRI correlates of brain astrocytosis, measured with 11C-deuterium-L-deprenyl (11C-DED)–PET, in familial autosomal-dominant Alzheimer disease (ADAD).MethodsThe total sample (n = 31) comprised ADAD mutation carriers (n = 10 presymptomatic, 39.2 ± 10.6 years old; n = 3 symptomatic, 55.5 ± 2.0 years old) and noncarriers (n = 18, 44.0 ± 13.7 years old) belonging to families with mutations in either the presenilin-1 or amyloid precursor protein genes. All participants underwent structural and diffusion MRI and neuropsychological assessment, a

APA, Harvard, Vancouver, ISO, and other styles

4

Farid, Karim, Stephen F. Carter, Elena Rodriguez-Vieitez, et al. "Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition." Journal of Alzheimer's Disease 47, no. 3 (2015): 661–67. https://doi.org/10.3233/JAD-141965.

Full text

Abstract:

Amyotrophic lateral sclerosis (ALS), a fatal disease of unknown origin, affects motor neurons in the primary motor cortex, brainstem, and spinal cord. Cognitive impairment may occur before the motor symptoms. We present a patient who was initially diagnosed with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) but who developed ALS-like symptoms during follow-up and died shortly thereafter. A 60-year-old subject with cognitive impairment underwent neuropsychological testing, cerebrospinal fluid (CSF) analysis, structural imaging (computed tomography and magnetic resonance

APA, Harvard, Vancouver, ISO, and other styles

5

Rodriguez-Vieitez, E., S. F. Carter, K. Chiotis, et al. "Comparison of Early-Phase 11C-Deuterium-L-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease." Journal of Nuclear Medicine 57, no. 7 (2016): 1071–77. http://dx.doi.org/10.2967/jnumed.115.168732.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Rodriguez-Vieitez, Elena, Ruiqing Ni, Balázs Gulyás, et al. "Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study." Eur J Nucl Med Mol Imaging. 42, no. 7 (2015): 1119–32. https://doi.org/10.1007/s00259-015-3047-0.

Full text

Abstract:

PURPOSE: Pathological studies suggest that neuroinflammation is exacerbated by increased beta-amyloid (Aβ) levels in the brain early in Alzheimer's disease (AD). The time course and relationships between astrocytosis and Aβ deposition were examined using multitracer in vivo positron emission tomography (PET) imaging in an AD transgenic mouse model, followed by postmortem autoradiography and immunohistochemistry analysis. METHODS: PET imaging with the amyloid plaque tracer (11)C-AZD2184 and the astroglial tracer (11)C-deuterium-L-deprenyl ((11)C-DED) was carried out in APPswe mice

APA, Harvard, Vancouver, ISO, and other styles

7

Carter, S. F., M. Scholl, O. Almkvist, et al. "Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG." Journal of Nuclear Medicine 53, no. 1 (2012): 37–46. http://dx.doi.org/10.2967/jnumed.110.087031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rodriguez-Vieitez, Elena, Karen Butina, Stephen F. Carter, and Agneta Nordberg. "P3-214: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE." Alzheimer's & Dementia 10 (July 2014): P709. http://dx.doi.org/10.1016/j.jalz.2014.05.1305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fowler, J. S., A. P. Wolf, R. R. Macgregor, et al. "Probing the biochemical basis of the PET image. Mechanistic PET studies of [11C]L-deprenyl binding using the deuterium isotope effect." Journal of Labelled Compounds and Radiopharmaceuticals 26, no. 1-12 (1989): 236–37. http://dx.doi.org/10.1002/jlcr.25802601107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Rodriguez-Vieitez, Elena, Karen Butina, Stephen F. Carter, and Agneta K. Nordberg. "IC-03-03: COMPARISON OF MEASUREMENTS OF CEREBRAL BLOOD FLOW BY EARLY FRAMES OF 11C-DEUTERIUM-L-DEPRENYL (11C-DED) AND 11C-PIB PET TRACERS AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE." Alzheimer's & Dementia 10 (July 2014): P7. http://dx.doi.org/10.1016/j.jalz.2014.04.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Razifar, Pasha, Jan Axelsson, Harald Schneider, Bengt Långström, Ewert Bengtsson, and Mats Bergström. "A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies—Clinical brain studies using [11C]-GR205171, [11C]-l-deuterium-deprenyl, [11C]-5-Hydroxy-l-Tryptophan, [11C]-l-DOPA and Pittsburgh Compound-B." NeuroImage 33, no. 2 (2006): 588–98. http://dx.doi.org/10.1016/j.neuroimage.2006.05.060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Carter, Stephen F., Agneta Nordberg, Michael Schöll, et al. "O1-07-05: Investigating astrocytosis with 11C-deuterium-L-Deprenyl in mild cognitive impairment and mild Alzheimer's disease: A multi tracer PET paradigm combining 11C-PIB and 18F-FDG." Alzheimer's & Dementia 7 (July 2011): S110. http://dx.doi.org/10.1016/j.jalz.2011.05.276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Fowler, J. S., A. P. Wolf, R. R. MacGregor, et al. "Mechanistic Positron Emission Tomography Studies: Demonstration of a Deuterium Isotope Effect in the Monoamine Oxidase-Catalyzed Binding of [11C]l-Deprenyl in Living Baboon Brain." Journal of Neurochemistry 51, no. 5 (1988): 1524–34. http://dx.doi.org/10.1111/j.1471-4159.1988.tb01121.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rodriguez-Vieitez, Elena, Laure Saint-Aubert, Stephen F. Carter, et al. "Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease." Brain 139 (January 26, 2016): 922–36. https://doi.org/10.1093/brain/awv404.

Full text

Abstract:

Alzheimer’s disease is a multifactorial dementia disorder characterized by early amyloid-b, tau deposition, glial activation and neurodegeneration, where the interrelationships between the different pathophysiological events are not yet well characterized. In this study, longitudinal multitracer positron emission tomography imaging of individuals with autosomal dominant or sporadic Alzheimer’s disease was used to quantify the changes in regional distribution of brain astrocytosis (tracer 11C-deuterium-L-deprenyl), fibrillar amyloid-b plaque deposition (11C-Pittsburgh compound B), a

APA, Harvard, Vancouver, ISO, and other styles

15

Meyer, Jeffrey H., and Joeffre Braga. "Development and Clinical Application of Positron Emission Tomography Imaging Agents for Monoamine Oxidase B." Frontiers in Neuroscience 15 (February 25, 2022). http://dx.doi.org/10.3389/fnins.2021.773404.

Full text

Abstract:

Monoamine oxidase B (MAO-B) is a high-density protein in the brain mainly found on outer mitochondrial membranes, primarily in astroglia, but additionally in serotonergic neurons and in the substantia nigra in the midbrain. It is an enzyme that participates in the oxidative metabolism of important monoamines including dopamine, norepinephrine, benzylamine, and phenylethylamine. Elevated MAO-B density may be associated with astrogliosis and inhibiting MAO-B may reduce astrogliosis. MAO-B density is elevated in postmortem sampling of pathology for many neuropsychiatric diseases including Alzheim

APA, Harvard, Vancouver, ISO, and other styles

16

Chiotis, Konstantinos, Charlotte Johansson, Elena Rodriguez-Vieitez, et al. "Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP." Molecular Neurodegeneration 18, no. 1 (2023). http://dx.doi.org/10.1186/s13024-023-00647-y.

Full text

Abstract:

Abstract Background Plasma assays for the detection of Alzheimer’s disease neuropathological changes are receiving ever increasing interest. The concentration of plasma glial fibrillary acidic protein (GFAP) has been suggested as a potential marker of astrocytes or recently, amyloid-β burden, although this hypothesis remains unproven. We compared plasma GFAP levels with the astrocyte tracer 11C-Deuterium-L-Deprenyl (11C-DED) in a multi-modal PET design in participants with sporadic and Autosomal Dominant Alzheimer’s disease. Methods Twenty-four individuals from families with known Autosomal Do

APA, Harvard, Vancouver, ISO, and other styles

17

Bellaver, Bruna, João Pedro Ferrari-Souza, Lucas Uglione da Ros, et al. "Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis." Neurology, May 5, 2021, 10.1212/WNL.0000000000012109. http://dx.doi.org/10.1212/wnl.0000000000012109.

Full text

Abstract:

Objective:To perform a systematic review and meta-analysis to determine whether fluid and imaging astrocyte biomarkers are altered in Alzheimer's disease (AD).Methods:PubMed and Web of Science databases were searched for articles reporting fluid or imaging astrocyte biomarkers in AD. Pooled effect sizes were determined with mean differences (SMD) using the Hedge’s G method with random-effects to determine biomarker performance. Adapted questions from QUADAS-2 were applied for quality assessment. A protocol for this study has been previously registered in PROSPERO (registration number: CRD42020

APA, Harvard, Vancouver, ISO, and other styles

18

Choo, Il Han, Stephen F. Carter, Michael Schöll, and Agneta Nordberg. "Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients." Eur J Nucl Med Mol Imaging, July 31, 2014. https://doi.org/10.1007/s00259-014-2859-7.

Full text

Abstract:

PURPOSE: The Alzheimer's disease (AD) pathology is characterized by fibrillar amyloid deposits and neurofibrillary tangles, as well as the activation of astrocytosis, microglia activation, atrophy, dysfunctional synapse, and cognitive impairments. The aim of this study was to test the hypothesis that astrocytosis is correlated with reduced gray matter density in prodromal AD. METHODS: Twenty patients with AD or mild cognitive impairment (MCI) underwent multi-tracer positron emission tomography (PET) studies with 11C-Pittsburgh compound B (11C-PIB), 18 F-Fluorodeoxyglucose (18&thinsp

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!